Biological relevance of citrullinations: Diagnostic, prognostic and therapeutic options

Autoimmunity

Volumn 48, Issue 2, 2015, Pages 73-79

  Gudmann, Natasja S ^a   Hansen, Niels U B ^a   Jensen, Anne C B ^a   Karsdal, Morten A ^a   Siebuhr, Anne S ^a  

^a NORDIC BIOSCIENCE A S   (Denmark)

Author keywords

Biomarker; citrullination; inflammatory disease; peptidylarginine deiminase

Indexed keywords

ANTICITRULLINATED PROTEIN ANTIBODY; ARGININE; BIOLOGICAL MARKER; CITRULLINE; PROTEIN ANTIBODY; PROTEIN ARGININE DEIMINASE; UNCLASSIFIED DRUG; AUTOANTIBODY; BENZAMIDINE DERIVATIVE; ENZYME INHIBITOR; HYDROLASE; ISOENZYME; PROTEIN-ARGININE DEIMINASE;

ANKYLOSING SPONDYLITIS; ANTIGEN ANTIBODY COMPLEX; CITRULLINATION; DIAGNOSIS; DISEASE ACTIVITY; DISEASE SEVERITY; ENZYME ACTIVITY; ENZYME INHIBITION; EXTRACELLULAR MATRIX; EXTRACELLULAR TRAP; FIBROSIS; HUMAN; IMMUNOLOGICAL TOLERANCE; MULTIPLE SCLEROSIS; NEUTROPHIL; NUCLEAR LOCALIZATION SIGNAL; PROTEIN PROCESSING; REVIEW; RHEUMATOID ARTHRITIS; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; BIOSYNTHESIS; IMMUNOLOGY; METABOLISM; NEOPLASMS; PATHOLOGY; SPONDYLITIS, ANKYLOSING;

ARGININE; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; BENZAMIDINES; BIOMARKERS; CITRULLINE; ENZYME INHIBITORS; FIBROSIS; HUMANS; HYDROLASES; ISOENZYMES; MULTIPLE SCLEROSIS; NEOPLASMS; PROTEIN PROCESSING, POST-TRANSLATIONAL; SPONDYLITIS, ANKYLOSING;

EID: 84924932110     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.3109/08916934.2014.962024     Document Type: Review

References (66)

1. Wegner, N., K. Lundberg, A. Kinloch, et al. 2010. Autoimmunity to specific citrullinated proteins gives the first clues to the etiology of rheumatoid arthritis. Immunol. Rev. 233: 34-54.
2. Van Venrooij, W. J., J. J. van Beers, and G. J. Pruijn. 2011. Anti-CCP antibodies: the past, the present and the future. Nat. Rev. Rheumatol. 7: 391-398.
3. Vossenaar, E. R., A. J. Zendman, W. J. Van Venrooij, and G. J. Pruijn. 2003. PAD, a growing family of citrullinating enzymes: genes, features and involvement in disease. BioEssays 25: 1106-1118.
4. De Ceuleneer, M., K. Van Steendam, M. Dhaenens, and D. Deforce. 2012. In vivo relevance of citrullinated proteins and the challenges in their detection. Proteomics 12: 752-760.
5. De, R. L., A. P. Nicholas, T. Cantaert, et al. 2005. Synovial intracellular citrullinated proteins colocalizing with peptidyl arginine deiminase as pathophysiologically relevant antigenic determinants of rheumatoid arthritis-specific humoral autoimmunity. Arthritis Rheum. 52: 2323-2330.
6. Gyorgy, B., E. Toth, E. Tarcsa, et al. 2006. Citrullination: a posttranslational modification in health and disease. Int. J. Biochem. Cell. Biol. 38: 1662-1677.
7. Guerrin, M., A. Ishigami, M. C. Mechin, et al. 2003. cDNA cloning, gene organization and expression analysis of human peptidylarginine deiminase type I. Biochem. J. 370: 167-174.
8. Moelants, E. A. V., A. Morier, J. van Damme, et al. 2012. Peptidylarginine deiminases: physiological function, interaction with chemokines and role in pathology. Drug Discov. Today Technol. 9: e261-e280.
9. Horibata, S., S. A. Coonrod, and B. D. Cherrington. 2012. Role for peptidylarginine deiminase enzymes in disease and female reproduction. J. Reprod. Dev. 58: 274-282.
10. Vossenaar, E. R., A. J. Zendman, W. J. Van Venrooij, and G. J. Pruijn. 2003. PAD, a growing family of citrullinating enzymes: genes, features and involvement in disease. BioEssays 25: 1106-1118.
11. Hagiwara, T., K. Nakashima, H. Hirano, et al. 2002. Determination of arginine residues in nucleophosmin/B23 and histones in HL-60 granulocytes. Biochem. Biophys. Res. Commun. 290: 979-983.
12. Wang, Y., M. Li, S. Stadler, et al. 2009. Histone hypercitrullination mediates chromatin decondensation and neutrophil extracellular trap formation. J. Cell Biol. 184: 205-213.
13. Chirivi, R. G. S., J. W. G. Rosmalen, G. J. Jenniskens, et al. 2013. Citrullination: a target for disease intervention in multiple sclerosis and other inflammatory diseases? J. Clin. Cell. Immunol. 4: 146.
14. Skriner, K., K. Adolph, P. R. Jungblut, and G. R. Burmester. 2006. Association of citrullinated proteins with synovial exosomes. Arthritis Rheum. 54: 3809-3814.
15. Kidd, B. A., P. P. Ho, O. Sharpe, et al. 2008. Epitope spreading to citrullinated antigens in mouse models of autoimmune arthritis and demyelination. Arthritis Res. Ther. 10: R119.
16. Lundberg, K., S. Nijenhuis, E. R. Vossenaar, et al. 2005. Citrullinated proteins have increased immunogenicity and arthritogenicity and their presence in arthritic joints correlates with disease severity. Arthritis Res. Ther. 7: R458-R467.
17. Khandpur, R., C. Carmona-Rivera, A. Vivekanandan-Giri, et al. 2013. NETs are a source of citrullinated autoantigens and stimulate inflammatory responses in rheumatoid arthritis. Sci. Transl. Med. 5: 178ra40.
18. Pritzker, L. B., S. Joshi, J. J. Gowan, et al. 2000. Deimination of myelin basic protein. 1. Effect of deimination of arginyl residues of myelin basic protein on its structure and susceptibility to digestion by cathepsin D. Biochemistry 39: 5374-5381.
19. Moscarello, M. A., F. G. Mastronardi, and D. D. Wood. 2007. The role of citrullinated proteins suggests a novel mechanism in the pathogenesis of multiple sclerosis. Neurochem. Res. 32: 251-256.
20. Vossenaar, E. R., A. J. Zendman, W. J. Van Venrooij, and G. J. Pruijn. 2003. PAD, a growing family of citrullinating enzymes: genes, features and involvement in disease. BioEssays 25: 1106-1118.
21. Snir, O., M. Widhe, S. C. von, et al. 2009. Multiple antibody reactivities to citrullinated antigens in sera from patients with rheumatoid arthritis: association with HLA-DRB1 alleles. Ann. Rheum. Dis. 68: 736-743.
22. Vossenaar, E. R., A. J. Zendman, W. J. Van Venrooij, and G. J. Pruijn. 2003. PAD, a growing family of citrullinating enzymes: genes, features and involvement in disease. BioEssays 25: 1106-1118.
23. Schuerwegh, A. J., A. Ioan-Facsinay, A. L. Dorjee, et al. 2010. Evidence for a functional role of IgE anticitrullinated protein antibodies in rheumatoid arthritis. Proc. Natl. Acad. Sci. USA 107: 2586-2591.
24. Suurmond, J., A. J. Schuerwegh, and R. E. Toes. 2011. Anti-citrullinated protein antibodies in rheumatoid arthritis: a functional role for mast cells and basophils? Ann. Rheum. Dis. 70: i55-i58.
25. Vossenaar, E. R., A. J. Zendman, W. J. Van Venrooij, and G. J. Pruijn. 2003. PAD, a growing family of citrullinating enzymes: genes, features and involvement in disease. BioEssays 25: 1106-1118.
26. Snir, O., M. Widhe, M. Hermansson, et al. 2010. Antibodies to several citrullinated antigens are enriched in the joints of rheumatoid arthritis patients. Arthritis Rheum. 62: 44-52.
27. Makrygiannakis, D., E. af Klint, I. E. Lundberg, et al. 2006. Citrullination is an inflammation-dependent process. Ann. Rheum. Dis. 65: 1219-1222.
28. Darrah, E., J. T. Giles, M. L. Ols, et al. 2013. Erosive rheumatoid arthritis is associated with antibodies that activate PAD4 by increasing calcium sensitivity. Sci. Transl. Med. 5: 186ra65.
29. Antoniou, K. M., K. D. Samara, I. Lasithiotaki, et al. 2011. Investigation of the citrullination pathway in the pathogenesis of fibrotic lung disorders: preliminary results.
30. Klareskog, L., P. Stolt, K. Lundberg, et al. 2006. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum. 54: 38-46.
31. Vassiliadis, E., S. S. Veidal, M. N. Kristiansen, et al. 2013. Peptidyl arginine deiminase inhibitor effect on hepatic fibrogenesis in a CCl4 pre-clinical model of liver fibrosis. Am. J. Transl. Res. 5: 465-469.
32. Abdeen, S., S. O. Olusi, and S. George. 2011. Serum anti-modified citrullinated vimentin antibody concentration is associated with liver fibrosis in patients with chronic hepatitis. Hepat. Med. 3: 13-18.
33. Aletaha, D., T. Neogi, A. J. Silman, et al. 2010. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 62: 2569-2581.
34. Pruijn, G. J., A. Wiik, and W. J. Van Venrooij. 2010. The use of citrullinated peptides and proteins for the diagnosis of rheumatoid arthritis. Arthritis Res. Ther. 12: 203.
35. Rantapaa-Dahlqvist, S., B. A. de Jong, E. Berglin, et al. 2003. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum. 48: 2741-2749.
36. Sanmarti, R., S. Cabrera-Villalba, J. A. Gomez-Puerta, et al. 2012. Palindromic rheumatism with positive anticitrullinated peptide/protein antibodies is not synonymous with rheumatoid arthritis: a longterm followup study. J. Rheumatol. 39: 1929-1933.
37. Orge, E., A. Cefle, A. Yazici, et al. 2010. The positivity of rheumatoid factor and anti-cyclic citrullinated peptide antibody in nonarthritic patients with chronic hepatitis C infection. Rheumatol. Int. 30: 485-488.
38. Papamichael, K., A. Tsirogianni, C. Papasteriades, and G. J. Mantzaris. 2010. Low prevalence of antibodies to cyclic citrullinated peptide in patients with inflammatory bowel disease regardless of the presence of arthritis. Eur. J. Gastroenterol. Hepatol. 22: 705-709.
39. Klareskog, L., J. Ronnelid, K. Lundberg, et al. 2008. Immunity to citrullinated proteins in rheumatoid arthritis. Annu. Rev. Immunol. 26: 651-675.
40. Amara, K., J. Steen, F. Murray, et al. 2013. Monoclonal IgG antibodies generated from joint-derived B cells of RA patients have a strong bias toward citrullinated autoantigen recognition. J. Exp. Med. 210: 445-455.
41. Karsdal, M. A., M. J. Nielsen, J. M. Sand, et al. 2013. Extracellular matrix remodeling: the common denominator in connective tissue diseases. Possibilities for evaluation and current understanding of the matrix as more than a passive architecture, but a key player in tissue failure. Assay. Drug Dev. Technol. 11: 70-92.
42. Lapolla, A., P. Traldi, and D. Fedele. 2005. Importance of measuring products of non-enzymatic glycation of proteins. Clin Biochem. 38: 103-115.
43. Henriksen, K., D. J. Leeming, I. Byrjalsen, et al. 2007. Osteoclasts prefer aged bone. Osteoporos. Int. 18: 751-759.
44. Doyle H. A., M. L. Yang, M. T. Raycroft, et al. 2013. Autoantigens: novel forms and presentation to the immune system. Autoimmunity. 47: 220-233.
45. Atassi, M. Z. and P. Casali. 2008. Molecular mechanisms of autoimmunity. Autoimmunity 41: 123-132.
46. Heidari, B. 2013. C-reactive protein and other markers of inflammation in hemodialysis patients. Caspian. J. Intern. Med. 4: 611-616.
47. Karsdal, M. A., K. Henriksen, D. J. Leeming, et al. 2010. Novel combinations of post-translational modification (PTM) neo-epitopes provide tissue-specific biochemical markers-are they the cause or the consequence of the disease? Clin. Biochem. 43: 793-804.
48. Bauer, D. C., D. J. Hunter, S. B. Abramson, et al. 2006. Classification of osteoarthritis biomarkers: a proposed approach. Osteoarthritis Cartilage 14: 723-727.
49. Veidal, S. S., A. C. Bay-Jensen, G. Tougas, et al. 2010. Serum markers of liver fibrosis: combining the BIPED classification and the neo-epitope approach in the development of new biomarkers. Dis. Markers 28: 15-28.
50. Schaller, S., K. Henriksen, P. Hoegh-Andersen, et al. 2005. In vitro, ex vivo, and in vivo methodological approaches for studying therapeutic targets of osteoporosis and degenerative joint diseases: how biomarkers can assist? Assay. Drug Dev. Technol. 3: 553-580.
51. Bay-Jensen, A. C., S. Wichuk, I. Byrjalsen, et al. 2013. Circulating protein fragments of cartilage and connective tissue degradation are diagnostic and prognostic markers of rheumatoid arthritis and ankylosing spondylitis. PLoS. One. 8: e54504.
52. Karsdal, M. A., K. Henriksen, D. J. Leeming, et al. 2010. Novel combinations of post-translational modification (PTM) neo-epitopes provide tissue-specific biochemical markers-are they the cause or the consequence of the disease? Clin. Biochem. 43: 793-804.
53. Saeki, Y., E. Kudo-Tanaka, S. Ohshima, et al. 2013. Baseline anti-citrullinated peptide antibody (ACPA) titers and serum interleukin-6 (IL-6) levels possibly predict progression of bone destruction in early stages of rheumatoid arthritis (ERA). Rheumatol. Int. 33: 451-456.
54. Siebuhr, A. S., A. C. Bay-Jensen, D. J. Leeming, et al. 2013. Serological identification of fast progressors of structural damage with rheumatoid arthritis. Arthritis Res. Ther. 15: R86.
55. Sokolove, J., R. Bromberg, K. D. Deane, et al. 2012. Autoantibody epitope spreading in the pre-clinical phase predicts progression to rheumatoid arthritis. PLoS. One. 7: e35296.
56. Karsdal, M. A., C. Christiansen, C. Ladel, et al. 2013. Osteoarthritis - a case for personalized health care? Osteoarthritis. Cartilage. 22: 7-16.
57. Isaacs, J. D., S. B. Cohen, P. Emery, et al. 2013. Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis. Ann. Rheum. Dis. 72: 329-336.
58. Vassiliadis, E., C. P. Oliveira, M. R. vares-da-Silva, et al. 2012. Circulating levels of citrullinated and MMP-degraded vimentin (VICM) in liver fibrosis related pathology. Am. J. Transl. Res. 4: 403-414.
59. Sailer, M., C. Dahlhoff, P. Giesbertz, et al. 2013. Increased plasma citrulline in mice marks diet-induced obesity and may predict the development of the metabolic syndrome. PLoS One 8: e63950.
60. Jones, J. E., C. P. Causey, B. Knuckley, et al. 2009. Protein arginine deiminase 4 (PAD4): current understanding and future therapeutic potential. Curr. Opin. Drug Discov. Dev. 12: 616-627.
61. Willis, V. C., A. M. Gizinski, N. K. Banda, et al. 2011. N-alpha-benzoyl-N5-(2-chloro-1-iminoethyl)-L-ornithine amide, a protein arginine deiminase inhibitor, reduces the severity of murine collagen-induced arthritis. J. Immunol. 186: 4396-4404.
62. Chumanevich, A. A., C. P. Causey, B. A. Knuckley, et al. 2011. Suppression of colitis in mice by Cl-amidine: a novel peptidylarginine deiminase inhibitor. Am. J. Physiol Gastrointest. Liver Physiol 300: G929-38.
63. Slack, J. L., C. P. Causey, and P. R. Thompson. 2011. Protein arginine deiminase 4: a target for an epigenetic cancer therapy. Cell. Mol. Life Sci. 68: 709-720.
64. Wang, Y., P. Li, S. Wang, et al. 2012. Anticancer peptidylarginine deiminase (PAD) inhibitors regulate the autophagy flux and the mammalian target of rapamycin complex 1 activity. J. Biol. Chem. 287: 25941-25953.
65. Knight, J. S., W. Zhao, W. Luo, et al. 2013. Peptidylarginine deiminase inhibition is immunomodulatory and vasculoprotective in murine lupus. J. Clin. Invest. 123: 2981-2993.
66. Lange, S., S. Gogel, K. Y. Leung, et al. 2011. Protein deiminases: new players in the developmentally regulated loss of neural regenerative ability. Dev. Biol. 355: 205-214.